Therapy News and Research

RSS

Blood test that predicts seriousness of a head injury gains momentum

A blood test that can help predict the seriousness of a head injury and detect the status of the blood-brain barrier is a step closer to reality, according to two recently published studies involving University of Rochester Medical Center researchers.

31 Mar 2009

Ultrasound saves money, improves rheumatologic care

A few years back, 76-year-old Joseph Buggie woke up to pain so throbbing, he couldn't muster the strength to roll over, let alone crawl out of bed.

31 Mar 2009

Basilea Pharmaceutica expands potential commercial availability of Toctino in Europe

Basilea Pharmaceutica Ltd. has announced the submission of a Marketing Authorization Application (MAA) for Toctino (alitretinoin) in 13 additional European Union (EU) Member States as well as in Norway and Iceland. Toctino is a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids.

31 Mar 2009

The clinical availability of CT colonography

Computed tomographic (CT) colonography allows the visualization of extracolonic organs, thereby permitting the detection of potentially significant pathologies beyond the colon.

30 Mar 2009

SARcode announces results of phase 1 trial of SAR 1118 ophthalmic solution in healthy adult subjects

SARcode Corporation announced today the results of its Phase 1 randomized, double-masked, placebo-controlled trial of the safety, tolerability, and pharmacokinetics of single- and multiple-escalating doses of SAR 1118 Ophthalmic Solution in healthy volunteers.

30 Mar 2009

New radiation-free targeted therapy detects and eliminates breast cancer tumors in mice

Combining a compound known as a gallium corrole with a protein carrier results in a targeted cancer therapy that is able to detect and eliminate tumors in mice with seemingly fewer side effects than other breast-cancer treatments, says a team of researchers from the California Institute of Technology (Caltech), the Israel Institute of Technology (Technion) and the Cedars-Sinai Medical Center.

30 Mar 2009

Mutations within a conservative region of hepatitis C virus affect therapy

At least 200 million individuals are currently infected with hepatitis C virus (HCV) worldwide.

30 Mar 2009

Improving cancer therapy achieved through taste, odor intervention

Cancer and its therapies, including chemotherapy and radiotherapy, may directly alter and damage taste and odor perception, possibly leading to patient malnutrition, and in severe cases, significant morbidity, according to a Virginia Tech - Wake Forest University Comprehensive Cancer Center compilation of various existing studies.

30 Mar 2009

Eye cells believed to be retinal stem cells are misidentified

Cells isolated from the eye that many scientists believed were retinal stem cells are, in fact, normal adult cells, investigators at St. Jude Children's Research Hospital have found.

30 Mar 2009

New cancer genomics web-based tools provide researchers a powerful new to visualize and analyze data

A Cancer Genomics Browser developed by researchers at the University of California, Santa Cruz, provides a new way to visualize and analyze data from studies aimed at improving cancer treatment by unraveling the complex genetic roots of the disease.

30 Mar 2009

Potential therapeutic strategy for fulminant hepatic failure

Fulminant hepatic failure is a serious clinical disease and may threaten the life of patients. However, because of the damage of mass liver cells, the organ function is often irreversible due to the liver cell degeneration, swelling, or apoptosis.

30 Mar 2009

New molecular marker of gastric cancer

Gastric cancer (GC) is one of the most common malignancies in the world with a high incidence and death rate.

30 Mar 2009

Missing enzyme GNSOR conveys major heart protection in pre-clinical work

Mice born without a certain enzyme can resist the normal effects of a heart attack and retain nearly normal function in the heart's ventricles and still-oxygenated heart tissue, according to a study by researchers at Duke University Medical Center.

30 Mar 2009

South Carolina audit finds inadequacies in Medicaid transportation service program

The South Carolina Legislative Audit Council, the investigative arm of the General Assembly, on Wednesday released an audit report finding that the state might have improperly managed the Medicaid transportation program, the Columbia State reports.

30 Mar 2009

FDA approves Afinitor oral tablets (everolimus) for advanced form of kidney cancer

The U.S. Food and Drug Administration today approved Afinitor oral tablets (everolimus) for the treatment of patients with advanced kidney cancer whose disease has progressed after treatment with other cancer therapies.

30 Mar 2009

The spread of drug resistant HIV-1

Drug-resistant forms of HIV can be spread between individuals who have not received anti-retroviral treatment, according to Professor Deenan Pillay from University College, London and the Health Protection Agency, speaking at the Society for General Microbiology meeting at Harrogate.

30 Mar 2009

Targeted drug therapy prevents exercise-induced arrhythmias

A 12-year-old Dutch boy - bedridden for three years because of an inherited cardiac arrhythmia syndrome - can now join his friends on the soccer field thanks to a discovery made by Vanderbilt University Medical Center researchers.

30 Mar 2009

Corthera's Relaxin in acute heart failure shows promising results

Corthera Inc. has announced that results from Pre-RELAX-AHF, the Phase II portion of a Phase II/III multicenter, randomized, double-blind, placebo-controlled international study, demonstrated promising efficacy and safety for relaxin, the company's investigational drug for treatment of acute heart failure (AHF).

30 Mar 2009

Angiogenesis inhibitor improves glioblastoma survival by reducing edema

The beneficial effects of anti-angiogenesis drugs in the treatment of the deadly brain tumors called glioblastomas appear to result primarily from reduction of edema - the swelling of brain tissue - and not from any direct anti-tumor effect, according to a study from Massachusetts General Hospital (MGH) researchers.

30 Mar 2009

NTRILIPIX (fenofibric acid) in combo with Rosuvastatin calcium shows improvement on key lipids for cholesterol management

Data from a new study showed that Abbott's TRILIPIX (fenofibric acid) delayed-release capsules in combination with rosuvastatin calcium met all of the study's primary endpoints.

29 Mar 2009

Therapy News and Research

Blood test that predicts seriousness of a head injury gains momentum

Ultrasound saves money, improves rheumatologic care

Basilea Pharmaceutica expands potential commercial availability of Toctino in Europe

The clinical availability of CT colonography

SARcode announces results of phase 1 trial of SAR 1118 ophthalmic solution in healthy adult subjects

New radiation-free targeted therapy detects and eliminates breast cancer tumors in mice

Mutations within a conservative region of hepatitis C virus affect therapy

Improving cancer therapy achieved through taste, odor intervention

Eye cells believed to be retinal stem cells are misidentified

New cancer genomics web-based tools provide researchers a powerful new to visualize and analyze data

Potential therapeutic strategy for fulminant hepatic failure

New molecular marker of gastric cancer

Missing enzyme GNSOR conveys major heart protection in pre-clinical work

South Carolina audit finds inadequacies in Medicaid transportation service program

FDA approves Afinitor oral tablets (everolimus) for advanced form of kidney cancer

The spread of drug resistant HIV-1

Targeted drug therapy prevents exercise-induced arrhythmias

Corthera's Relaxin in acute heart failure shows promising results

Angiogenesis inhibitor improves glioblastoma survival by reducing edema

NTRILIPIX (fenofibric acid) in combo with Rosuvastatin calcium shows improvement on key lipids for cholesterol management

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News